SN
Santen Pharmaceutical Co., Ltd.
SNPHF · OTC
$10.99 -15.79% (-$2.06)
Market Cap ¥555.1B
P/E Ratio 14.29x
Div. Yield 2.25%
ROE 17.61%
Bulios Fair Price
$14.33
30.4% upside
Current Price
$10.99
Undervalued Fair Value Overvalued
According to Bulios Fair Price, SNPHF is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Strong
8/9Valuation
89 /100
Cheap P/E 14.29x
EV/EBITDA 7.78x
P/S 1.90x
Growth
62 /100
Stable EPS growth 15.11%
Rev. growth 4.06%
FCF growth 74.56%
Profitability
78 /100
Strong Gross margin 56.10%
Net margin 13.26%
Op. margin 15.69%
Quality
70 /100
Excellent ROIC 11.03%
ROE 17.61%
ROA 9.41%
Debt
100 /100
Low Debt/Equity 0.10x
Current ratio 2.82x
Int. coverage 23.50x
Stability
38 /100
Moderate Beta 0.24x
Rev. volatility 4.47%
EPS volatility 222.54%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about SNPHF
Online
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Takeshi Ito
Employees
3,968
Headquarters
Kita
Upcoming events
29 SEP
Ex-Dividend
Ex-dividend date
29 SEP
Dividend Payment
Payment date
05 NOV
Earnings
Upcoming earnings report
30 MAR
Ex-Dividend
Ex-dividend date
30 MAR
Dividend Payment
Payment date